Long Non-Coding RNA in Gastric Cancer: Mechanisms and Clinical Implications for Drug Resistance

Abstract

Gastric cancer (GC) is the third leading cause of cancer-related deaths worldwide, with high recurrence and mortality rate. Chemotherapy, including 5-fluorouracil (5-FU), adriamycin (ADR), vincristine (VCR), paclitaxel (PTX), and platinum drugs, remains one of the fundamental methods of GC treatment and has efficiently improved patients’ prognosis. However, most patients eventually develop resistance to chemotherapeutic agents, leading to the failure of clinical treatment and patients’ death. Recent studies suggest that long non-coding RNAs (lncRNAs) are involved in the drug resistance of GC by modulating the expression of drug resistance-related genes via sponging microRNAs (miRNAs). Moreover, lncRNAs also play crucial roles in GC drug resistance via a variety of mechanisms, such as the regulation of the oncogenic signaling pathways, inhibition of apoptosis, induction of autophagy, modulation of cancer stem cells (CSCs), and promotion of the epithelial-to-mesenchymal transition (EMT) process. Some of lncRNAs exhibit great potential as diagnostic and prognostic biomarkers, as well as therapeutic targets for GC patients. Therefore, understanding the role of lncRNAs and their mechanisms in GC drug resistance may provide us with novel insights for developing strategies for individual diagnosis and therapy. In this review, we summarize the recent findings on the mechanisms underlying GC drug resistance regulated by lncRNAs. We also discuss the potential clinical applications of lncRNAs as biomarkers and therapeutic targets in GC.

The regulatory function of piRNA/PIWI complex in cancer and other human diseases: The role of DNA methylation

“…Beyond the role of piRNAs and piRNA-associated methylation as biomarkers, several studies have put forward their potential role as therapeutic tools 44 , 78 , 109 , 149 just like other non-coding RNAs 150 - 152 . On the basis of the functional characteristics of piRNAs, we offer some thoughts on piRNA as a possible target for cancer therapy as follows.…”

The Targeting of Noncoding RNAs by Quercetin in Cancer Prevention and Therapy

“…lncRNAs have emerged as versatile players in gene regulation in multiple biological and physiopathological contexts, particularly cancer [ 79 ]. The number of lncRNAs involved in carcinogenesis and cancer progression is exponentially increasing.…”

The Role and Interactions of Programmed Cell Death 4 and its Regulation by microRNA in Transformed Cells of the Gastrointestinal Tract

“…LncRNAs are non-protein coding RNAs greater than two hundred nucleotides in length that can bind and consequentially inactivate (sponge) microRNAs. Changes in the expression of LncRNAs have been associated with multiple cancers ( 212 ) including oesophageal- ( 213 ), gastric- ( 214 ) and colorectal cancers ( 215 ). The authors found that NR2F2-AS1 is weakly expressed in gastric cancer tissue and in AGS, MGC-803, SGC-7901 and SNU-1 GC cell lines compared to normal cells and expression negatively correlated with poor prognosis and worse overall survival.…”